The women who say their contraceptive gave them brain tumours - The Telegraph

Direct Source Verification: This story is aggregated from The Telegraph (telegraph.co.uk). Full reporting rights and copyright belong to the primary publisher.
In January, a team of neurosurgeons performed a craniotomy to remove a benign, golf-ball-sized tumour – a meningioma – from my brain.

In January, a team of neurosurgeons performed a craniotomy to remove a benign, golf-ball-sized tumour – a meningioma – from my brain.

In the lead-up to the operation, even while I was told that my prognosis was good, the doctors had laboured heavily not just on the threat to my life but on what could happen after the operation. The tumour’s position, on top of my head rather than deeply embedded in the brain, would make surgery easier, but if things didn’t go perfectly, risks – aside from death – still included stroke, loss of speech and loss of the use of one side of my body.

I was devastated. Until then, I had lived a healthy life for 33 years; I had rarely even set foot inside a hospital and had never been under general anaesthetic, let alone faced a procedure as invasive as brain surgery. Coming to terms with this new medical reality was one of the hardest things I have ever had to do.

Luckily, my procedure went well. They managed to remove the tumour, and I was out of hospital in a matter of days. I felt raw and exhausted, but above all I was relieved. The whole experience was traumatic, but my first instinct was gratitude that I had seemed to come out relatively unscathed.

Then, three weeks into my recovery – and only days after the stitches had been removed from the crown of my head – I heard a news bulletin that made my blood run cold. A group of women was pursuing legal action after research found a link between the active ingredient in Depo-Provera, a widely used contraceptive injection, and the very type of tumour I had just had removed. I sat frozen for a moment before beginning a frantic search for more information.

Charley Ross lives with life-changing side effects after her craniotomy in January Credit: Laura Pannack History of the drugFirst synthesised in 1954, Depo-Provera’s active ingredient, the synthetic hormone medroxyprogesterone acetate (MPA), was the brainchild of a group of scientists at the Upjohn Company (now a business division of the pharmaceutical giant Pfizer).

In 1960, the US Food and Drug Administration approved it for treatment of endometriosis, uterine fibroids and certain types of cancer.

By the time the drug was licensed as a contraceptive in the UK in 1984, rumblings of problematic side effects had been ongoing for years. In fact, it had been rejected for use as a contraceptive in the US three times, in 1974, 1978 and 1983. In 1974, concerns were raised about the possibility of cancer risks, and animals tested with the drug were found to have developed malignant tumours in 1978.

Reports were also made of inadequate record-keeping, lost patient files and failure to track serious side effects, meaning that meaningful follow-up studies were difficult to carry out.

When the drug was finally approved for use as a method of contraception in the US in October 1992, there was public outcry. Advocacy groups such as the National Women’s Health Network were strongly opposed amid concerns about study objectivity and the potential health impacts on women.

But it would take another 30 years – and a landmark piece of research – for any objections to be reflected in the drug’s safety materials.

In 2024 a French study published in the British Medical Journal found that women who had used MPA for 12 months or more were 5.6 times as likely to develop a meningioma as women in a control group.

The women’s overall likelihood of developing a tumour remained low, but to Dr Noémie Roland, an assistant professor of pharmacoepidemiology at the University of Southern Denmark who was the study’s lead researcher, the findings stood out as “clinically concerning”.

“Meningiomas are generally uncommon tumours, so identifying a fivefold increased risk associated with a widely used medication immediately raises important public health questions,” she says.

While no causal links have been proved, Roland’s findings were concerning enough to prompt Depo-Provera’s manufacturer, Pfizer – in collaboration with the UK’s medicines regulator, the MHRA – to update the patient leaflet for the injection in the UK with a brain tumour warning in 2024.

Of course this is all information I came to learn long after my tumour was removed. I was first injected with Depo-Provera in early 2024, around the same time the BMJ study was published, but in the years I took the drug, I – like untold numbers of other women – was never told it might be linked to meningioma.

For a long time I thought of it as a miracle contraceptive. There was no daily pill to remember: just one injection every three months, which could even be self-administered (I chose to attend a sexual health clinic four times a year); it is also oestrogen-free and therefore considered safer for women who, like me, experience migraines.

According to Roland’s study, MPA was, as of 2019, estimated to be used for birth control by 74 million women, meaning that “the number of attributable meningiomas may be potentially high” worldwide.

In England, NHS figures show that the drug is prescribed around 60,000 times a month.

Legal action against Pfizer began in the US mere months after the BMJ study was published.

In the UK, Stacey Duffy, a 48-year-old teaching assistant from Goole in East Yorkshire, was one of the first women to sound the alarm. She learned of the correlation between MPA use and meningioma in 2024, after her local sexual health clinic cancelled her quarterly appointment to receive the injection.

Duffy was first prescribed Depo-Provera in her early 20s. At the time, she recalls her life being “fast-paced, full of energy and centred around building a future”. She was working administrative and reception roles, while “starting to map out” what she wanted to do in the long term.

“My husband and I were already together and building our life as a couple,” Duffy recalls. “I’ve always been someone who couldn’t sit still for long. I was really into fitness, running and getting outdoors as much as possible… Life was about momentum.”

For over 20 years she saw it as sensible family planning. She stopped using the injection after marrying her husband, when they decided to start a family. Their son, William, was born in 2006. “I got pregnant straight away,” she says. “We did try after him as well, but it didn’t seem to work… We thought, we’ve got one, that’s fine. So I went back on the injection because it had worked for me previously.”

Initially no reason was given why she could no longer have Depo-Provera, but after inquiring further she was shown a letter that the clinic had been sent by Pfizer, which said “there is a small increased risk of developing meningioma with high doses of medroxyprogesterone acetate, primarily after prolonged use”. Duffy recalls “a sense of dread and disbelief” at seeing these words. “​It was frightening because it suddenly made sense of every mystery symptom or head pain I’d ever experienced.”

In 2021, a meningioma had been found on Duffy’s optic nerve. She recalls going “back and forth” with doctors in the years leading up to the diagnosis complaining of brain fog and migraines but having her symptoms dismissed as stress. It took a trip to the opticians after experiencing “grittiness” in her right eye to finally get a diagnosis.

“I was rubbing it a lot, and every now and again it’d go a bit blurry,” she says. She rang her doctor but was referred to the opticians. Within 24 hours Duffy was being seen at an eye clinic. She was then urgently referred for X-rays that identified her meningioma.

“If it wasn’t for them, I don’t think it’d ever have been found,” she says of the opticians who initially investigated her symptoms. When surgeons performed a craniotomy, however, they were unable to remove all of the tumour. Since the procedure, Duffy has lost sight in her right eye. She completed radiotherapy treatment on the remaining tumour last year but is likely to need further treatment if it grows again. Her ordeal has been distressing for her family, not least her son. “He was only 15 when I was diagnosed; he’s 19 now, but he still worries constantly,” Duffy says. “If I’m out on my own, he always wants to know where I am and whether I’m safe.”

After receiving the letter from Pfizer, Duffy left the doctor’s surgery shocked and suspicious. Her first reaction was simply: “Oh, my God.” But once she had gathered herself, she began to ask questions. “It seemed like too much of a coincidence that I’ve had this meningioma and they’ve given me that letter,” she says.

She immediately began searching online for information about medical negligence, which led her to Fletchers – a UK law firm specialising in claims of serious injury and medical negligence. “They didn’t seem to know a lot about it themselves when I made contact,” she says. “I think they had to get a bit of advice about it, to be honest, to see if they could take the case on.”

Lisa Lunt, a Fletchers partner, says that when she first began to receive calls like Duffy’s, her reaction was one of “real sadness and disappointment”. Fletchers’s team that focuses on medical product liability had worked on claims against manufacturers of transvaginal mesh implants and Essure (contraceptive fibres that were implanted into the fallopian tubes of patients).

Both these devices were found to cause horrific damage in some cases, with legal scandals ensuing as hundreds of women sought compensation.

Lunt points out that “while it is too early to predict the ultimate scale or historical significance of the Depo-Provera litigation, the similarities with transvaginal mesh are undeniable.”

She adds that both cases involve “large numbers of women reporting serious harm following the use of products intended to improve or support their quality of life.”

Now Fletchers, as well as the law firms Austen Hays and Leigh Day, are compiling cases against Pfizer. Austen Hays’ partner Alicia Theuma says they are in conversation with around 400 women about the case and are hearing from roughly 10 more each week. Theuma says some common themes have emerged among the women who have come forward. Nearly all have had major brain surgery; many describe years of debilitating symptoms. “Lots of people have had to give up work, give up driving, no social or hobbies are undertaken anymore,” she says. “They’ve had to completely alter their lives.”

In the US an ongoing federal case is representing more than 6,400 women.

By the time my tumour was diagnosed in 2025, I had been receiving the contraceptive injection for almost two years.

My symptoms started in March of that year, in the middle of the night during a once-in-a-lifetime trip to Australia. Throbbing palpitations coursed up and down my right arm, the right side of my neck and the right side of my torso and leg. I could speak during the episodes but would often experience brain fog before and after – unable to text or coherently form thoughts. It was terrifying, and the episodes became more intense as the year went on, peaking in October with a trip to A&E on my birthday. I didn’t realise that these unpleasant “turns” were seizures until my tumour was diagnosed in December.

On the day of my diagnosis – dazed, but desperate to cling to some sense of normality – I attended my appointment for the next dose of Depo-Provera, unaware of any possible link between the drug and my tumour.

It’s an experience echoed by Lauren Lewington, a 35-year-old mother of two from North Wales. By the time she stopped her Depo-Provera injections in January 2025, she had undergone multiple brain surgeries.

Scientists including Roland, who led the 2024 study, believe that meningiomas may be “hormonally sensitive”. These tumours grow in the meninges – the protective layers of tissue surrounding the brain and spinal cord – and many contain progesterone receptors: proteins that can respond to progesterone and progesterone-like drugs, potentially influencing a tumour’s growth or behaviour.

This is partially why meningiomas are more common in women than men. Evidence of hormonal influence on meningioma growth in pregnancy has also been observed, says Roland: “previously silent meningiomas can enlarge and become symptomatic during pregnancy, while some tumours may stabilise or even decrease in size after delivery”.

Lunt points out that reports linking progesterone receptors in human meningioma cells date back decades. “So I struggle to understand why it was ever placed on the market when there are safer alternatives, or at the very least without warnings until 2024.”

The first time Lewington was offered the contraceptive injection in 2009, she was 17, studying childcare at college and living at home with her family in the Welsh town of Bethesda. She was single when she started taking Depo-Provera but met Aaron soon after. They’ve been together 15 years, and married in 2024 in Bangor. “It was one of the best days of my life from start to finish, and the beautiful, hot weather made it even more special,” she says. Their son Jacob was born in August 2013, followed by Theodore (Theo) in June 2017. She was taking Depo-Provera throughout this time, for over 15 years – taking breaks only for pregnancies.

“Before my diagnosis, motherhood was great and I had no health problems,” Lewington says. “I had returned to college to study an A-level in childcare, as my goal was to work with SEN children. My husband and I were looking forward to the future with our boys, making memories and enjoying life together as a family.”

Both of Lewington’s sons have autism, which she describes as “always a big part of our lives”. “From around the age of three, we were fighting to get them diagnosed and make sure they received the right support,” she explains. Lewington now describes how her sons’ need for routine has helped motivate and ground her as she navigates the pain and side effects of both her tumour and multiple surgeries.

Because in 2022, she began experiencing crippling ear and head pain. “I went to my GP and was told it could be migraines,” she recalls. “But the pain would come on so suddenly, and nothing seemed to help. One day I had what they call a ‘thunder-clap’ headache. It felt like I’d been hit with a baseball bat. I was in pure agony on the way to hospital, I just wanted it to stop.” Over the next few months, Lewington made multiple visits to hospital, often arriving by ambulance. “I physically couldn’t walk at times. I had dizzy spells and these unbearable headaches.”

When doctors finally identified a mass on her brain as a meningioma, Lewington recalls feeling “completely overwhelmed”. “I went home without really understanding what that meant or what it was going to mean for my life.

“My neurologist…basically said to go home and enjoy Christmas. I remember going home and immediately thinking the worst – that I had cancer. I was completely numb when I got home and could barely even speak to my husband about it. I didn’t really know how to process what I had just been told.”

Since her ordeal began in July 2022 she has undergone three brain surgery procedures, as well as radiotherapy. After her third operation, doctors told her they couldn’t operate any further on her tumour because what was left of it was near critical blood vessels. “It’s heartbreaking to know that I’ll never be tumour-free,” she tells me.

Lewington was then told the part of the tumour that was removed tested 80 per cent progesterone-receptor positive. Only at this point was she asked whether she was on hormonal contraception – and was immediately told by her surgeon to stop taking Depo-Provera.

Lewington now lives with both trigeminal neuralgia and anaesthesia dolorosa from nerve damage. These two conditions are among the most severe forms of pain known to medicine. “The pain is nicknamed the ‘suicide pain’ because it can be so unbearable,” she says.

It’s such that Lewington has lost her connection with her life pre-diagnosis. “This head pain does not go away, no matter what I do. Even if I do get a good day, I’m thinking: ‘When is this head pain going to kick in?’… There are times when I honestly don’t know how much more I can take.”

Her ordeal has changed her life, but the part she is most devastated about is that she is unable to take care of Jacob and Theodore without help.

She also doesn’t feel able to return to work: “The severity and unpredictability of my attacks would make it difficult for any employer to keep me in a job, and I would not feel safe working with children in case an attack happened. It has completely changed my life.”

Indeed many women now face lifetimes of pain and suffering. Felicity Fisher, a 45-year-old solicitor from Burton-on-Trent, started taking Depo-Provera as a university student after it was recommended as a way to treat debilitating period pain.

She had been on the drug for more than two decades when she developed problems with her vision, and in 2023 she was diagnosed with a meningioma that had wrapped around her optic nerve. During her craniotomy, surgeons found other meningioma tumours around her skull that they were unable to remove because of their proximity to her spinal area. “I’ve accepted that these tumours are something I’ll probably be living with for the rest of my life,” she says. Fisher has lost around 75 per cent of the vision in her left eye because of irreversible damage to her optic nerve. “My optic nerve is dead. It won’t regenerate, so my sight isn’t coming back,” she says.

Danielle Watts, meanwhile, says her treatment has left her with a brain injury that affects her cognitive abilities. “My memory has completely changed. People tell me I’ve already told them something, but I genuinely don’t remember. I struggle with left and right, I’m having therapy for my cognitive problems and I just don’t feel like the same person anymore,” she says. The 46-year-old – who works in education – took Depo-Provera for almost two decades. Doctors told her to stop taking the injection in 2022 in an attempt to monitor her hormone levels, as she was having debilitating migraines. The following year, she experienced a disturbing flare-up in her right eye. “It swelled so much it felt like it was popping out of my head, and I was in excruciating pain,” she says. Watts had surgery later that year to remove a tumour and reposition her eye, which the swelling had displaced.

Both women are now represented by Fletchers, exploring cases against Pfizer.

Nicola Kingdon, 42, from Macclesfield, took Depo-Provera for over 10 years after first being prescribed it to alleviate her heavy periods. Her meningioma symptoms began with arm pain – from her elbow down past her wrist to her hand – which her GP dismissed as a pulled muscle. A few days later, while she was at work at a supermarket, a friend became alarmed, pointing out that the left side of her face had “dropped”. She was sent to a medical stroke unit and had a series of tests, which resulted in a meningioma diagnosis.

She received treatment for a blood clot in her brain before having a 10-hour craniotomy to remove the meningioma. She has been left with double vision in one eye and says changes to her appearance from the surgery have significantly affected her confidence. Her recovery has also been complicated by problems with her craniotomy wound.

When it comes to joining the legal action, Kingdon hopes the legal action will help draw public attention to the potential risks of Depo-Provera. “It angers me to think how many people could still be taking it now, teenagers who could end up going through what I’m going through now. Women and girls should be aware if there is a link between the jabs and meningioma tumours.”

It’s a sentiment echoed by Watts: “I can’t change what’s happened to me, but I do want other women to ask questions, understand the potential risks and make informed decisions about any medication they’re taking.”

By the time Ross’s tumour was diagnosed in 2025, she had been receiving the contraceptive injection for almost two years Credit: Laura Pannack Inconsistent responsesAfter I discovered the possibility of a link between Depo-Provera and my tumour, I tried to broach the subject with my neurosurgical team – I simply wasn’t sure who else to ask. My emails went unanswered, and when I asked one surgeon about it in person, he responded that it wasn’t his area of expertise.

Many women I’ve since spoken to have faced similar responses from medical teams. “There’s just such a failure to listen,” says Sarah Samuel, a medical product liability solicitor at Fletchers, saying that, in many instances, women’s pain was “dismissed, minimised or normalised”.

In June of this year, a group of women visited the Scottish Parliament in Holyrood to discuss their concerns about a “medical scandal” with a cross-party group of Scottish Members of Parliament. Alongside the lawsuit, Lunt and Samuel are looking to take the case into the political sphere in England too. “We’re looking at running a campaign to put pressure on Westminster to raise awareness… [perhaps via] a public inquiry into what was known [about Depo-Provera] and when, and about the risks and why people weren’t warned about it.

“[We’re also looking at] whether there ought to be some kind of medical testing as a matter of routine for people that have been taking Depo-Provera for a long period of time.”

As a result of the BMJ study, rules and regulations around how Depo-Provera is prescribed have shifted in many other countries. The Austen Hays solicitor Rachel Bright tells me that in France, for instance, Depo-Provera is now prescribed only “if no other contraception works for you”. “If at any point during treatment you present with meningioma symptoms,” she says, “you are sent straight for an MRI.”

Currently, the NHS website advises that having the injection “for three years or longer may increase your chance of getting a type of brain tumour called meningioma” but stresses that “this type of brain tumour is rare, so your chance of getting it is still quite small”.

Ten months after my craniotomy, I live with life-changing side effects, as do many of the women I met while reporting this article: a fatigue that no amount of sleep seems able to shift; brain fog; headaches. The women I’ve spoken with also report suffering from mood swings, changes in balance and depth perception as well as sight and memory loss.

And, like them, I am left with questions. Why was I given a dose of Depo-Provera on the very day of my meningioma diagnosis, despite guidelines that advise otherwise? Why were my doctors unwilling to discuss the reported link between the drug and my tumour? And why have UK guidelines on Depo-Provera not been updated in line with those in other countries?

In the US, legal analysis of the scientific evidence surrounding the correlation between Depo-Provera and an increased risk of meningioma suggests that the research is strongly favourable to claimants pursuing cases against Pfizer.

That could prove highly significant for UK legal teams. The Fletchers team has been liaising with lawyers in the United States. “It’s much harder to succeed in England than it is in the US,” Samuel, the medical product liability solicitor at Fletchers, explains. “So that’s why it is really promising, having spoken to the US lawyers, that they’re saying the science is strong because that’s what we need in England in order to bring [Pfizer] to the table.”

Of course, no amount of money will bring back the lives we had before. Every woman I have spoken with who has joined the action against Pfizer has described losing not only her independence, but also her sense of self. I feel the same. None of us are the women we were before these medical horrors unfolded. But we are determined to raise the alarm as best we can – so that future generations, and other women, can make the informed choices that we were never given.

A spokesman for Pfizer said: Patient safety is our top priority. We conduct rigorous and continuous monitoring of all our medicines, including assessments of reported adverse events.

In 2024, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) initiated a Signal Management procedure to investigate the risk of meningioma with the long-term use of medroxyprogesterone acetate (MPA). Pfizer participated fully in this process. Although the relative risk of meningioma is significantly increased with the use of high-dose medroxyprogesterone acetate, the absolute risk is very small. Product information and patient information leaflet were updated to reflect this potential risk. In agreement with the MHRA, a direct healthcare professional communication was issued in 2024 to ensure healthcare professionals were directly informed.

We would encourage people to speak to their doctor, pharmacist or nurse if they have any concerns or experience any side effects.

Product information [and the Patient Information Leaflet were] updated in 2024 [and] early 2025 following studies which showed a very small risk of meningioma associated with use of high-dose MPA… However, we are aware that the risk of meningioma may not be well recognised amongst healthcare professionals or patients [and are] considering what further communications are needed. 

For the majority of people, the benefits of Depo-Provera outweigh the risk, but we advise anyone with any concerns to speak with their GP, pharmacist or contraceptive provider.

Original Source
https://www.telegraph.co.uk/real-life/2026/11/16/women-contraceptives-brain-tumours/
Visit The Telegraph ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health